| CP | candle power; capillary pressure; cardiac pacing; cardiac performance; cardiopulmonary; caudate puta... |
|---|---|
| CRP | chronic relapsing pancreatitis; corneal-retinal potential; coronary rehabilitation program; C-reacti... |
| CSP | carotid sinus pressure; cavum septi pellucidi; cell surface protein; cerebrospinal protein; Chartere... |
| MCP | maximum closure pressure; maximum contraction pattern; malanocortin receptor; melphalan, cyclophosph... |
| SCP | single-celled protein; standard care plan; sodium cellulose phosphate; soluble cytoplasmic protein; ... |
| death, sudden | The sudden cessation of all vital bodily functions. Legally and medically, this includes the permanent cessation of total cerebral function, spontaneous function of the respiratory system, and spontaneous function of the circulatory system. (12 Dec 1998) |
|---|---|
| death, sudden, cardiac | The sudden cessation of cardiac contraction, leading to death of the heart and, ultimately, of the individual, resulting from ventricular tachycardia-fibrillation or asystole. (12 Dec 1998) |
| death trance | A condition of suspended animation, marked by unconsciousness and barely perceptible respiration and heart action. (05 Mar 2000) |
| direct maternal death | Death resulting from obstetric complications of the gestation, labour, or puerperium, and from interventions, omissions, incorrect treatment, or a chain of events caused by any of the above, indirect maternal death, an obstetric death resulting from previously existing disease or from disease developing during pregnancy, labour, or the puerperium; it is not directly due to obstetric causes, but to conditions aggravated by the physiological effects of pregnancy. (05 Mar 2000) |
| infant death | Death of a liveborn infant within the first year. (05 Mar 2000) |
| early neonatal death | Death of a liveborn infant occurring less than 7 completed days (168 hours) from the time of birth, late neonatal death, death of a liveborn infant occurring after 7 completed days of age but before 28 completed days. (05 Mar 2000) |
| foetal death | <radiology> No foetal movement, no foetal heart movement, scalp oedema, Spalding's sign, hyperextended spine, thrombus within heart (12 Dec 1998) |
| foetal death rate | The number of foetal deaths divided by the sum of live births and foetal deaths occurring in the same population during the same time period. Synonym: stillbirth rate. (05 Mar 2000) |
| local death | Death of a part of the body or of a tissue by necrosis. (05 Mar 2000) |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| acyl-(acyl-carrier-protein)-phospholipid acyltransferase | <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine Registry number: EC 2.3.1.40 Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase (26 Jun 1999) |
| acyl-(acyl-carrier-protein)-UDP-N-acetylglucosamine acyltransferase | <enzyme> E coli enzyme involved in lipid a biosynthesis; uses beta-hydroxymyristoyl-acyl carrier protein to form udp-3-monoacyl-n-acetylglucosamine; amino acid sequence given in second source Registry number: EC 2.3.1.129 Synonym: udp-aguatransferase, lpxa protein, udp-n-acetylglucosamine-3-acyltransferase, udp-n-acetylglucosamine 3-o-acyltransferase, udp-3-o-(r-3-hydroxymyristoyl)glucosamine-n-acyltransferase, lpxd protein, fira gene product, fira protein (26 Jun 1999) |
| acyl carrier protein | <protein> A small (77 peptides long) protein which binds six other enzymes involved in fatty acid synthesis. It was first isolated in E. Coli bacteria. (09 Oct 1997) |